Thrivent Financial for Lutherans
SYRS

Thrivent Financial for Lutherans’s Syros Pharmaceuticals, Inc. Common Stock SYRS Stock Holding History

Thrivent Financial for Lutherans’s Portfolio SYRS Stock Details SYRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-1,124
Closed -$122K – 2570
2020
Q4 		$122K Buy
+1,124
New +$103K ﹤0.01% 2436

Other funds holding SYRS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ABG
Ally Bridge Group New York $124M AUM 249.88% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return

Thrivent Financial for Lutherans's SYRS Position: Q1 2021 in Review

Thrivent Financial for Lutherans sold out of Syros Pharmaceuticals, Inc. Common Stock (SYRS) in Q1 2021, closing a stake of 1,124 shares — an estimated $122K sold.

Thrivent Financial for Lutherans first reported a position in SYRS in Q4 2020 and held it in 1 quarter. The position peaked at $122K in Q4 2020. 106 funds tracked by Wall St. Rank hold SYRS as of Q1 2021.

  • Thrivent Financial for Lutherans reported no remaining Syros Pharmaceuticals, Inc. Common Stock position as of Q1 2021 after selling out during the quarter.
  • Thrivent Financial for Lutherans sold 1,124 Syros Pharmaceuticals, Inc. Common Stock shares in Q1 2021, an estimated $122K.
  • Thrivent Financial for Lutherans first reported a position in Syros Pharmaceuticals, Inc. Common Stock in Q4 2020 and held it in 1 quarter.
  • Thrivent Financial for Lutherans's Syros Pharmaceuticals, Inc. Common Stock position peaked at $122K in Q4 2020.
  • 106 funds tracked by Wall St. Rank held Syros Pharmaceuticals, Inc. Common Stock as of Q1 2021.

Based on Thrivent Financial for Lutherans's 13F filing for Q1 2021, filed 17 May 2021.